Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1757)	8/3/2003 6:51:50 PM
From: tom pope	Respond to of 3044

[I wonder if they are cheering at Titan?] It's more the TTP shareholders who need something to cheer about, no?

To: Icebrg who wrote (1757)	8/7/2003 7:03:31 PM
From: Icebrg	Read Replies (2) \| Respond to of 3044

The Medicines Company Report - Angiomax Judging from MDCO's recent Q2-report Angiomax has not really started to move yet. Revenue development over the last 6 quarters. Q2_03 Q1_03 Q4_02 Q3_02 Q2_02 Q1_02 Revenue 18,8 16,7 14,3 9,1 7,2 7,7 MDCO will not specify its revenue any further. Some of the revenue might actually come from other sources. But in their 10K they wrote that most of it comes from Angiomax. Looking at these figures it does not look as if the slow-down in Integrelin sales is due to increasing competition from Angiomax. Erik